For decades, conversations about sex after menopause have often been treated like an awkward family group chat: everyone knows it exists, but nobody wants to bring it up. That is beginning to change. In late 2025, the U.S. Food and Drug Administration expanded the approved use of Addyi (flibanserin), a prescription medication for hypoactive sexual desire disorder, to include women younger than 65 regardless of reproductive status. In plain English, that means eligible postmenopausal women under age 65 may now have an FDA-approved medication option for persistent, distressing low sexual desire.
That does not mean menopause automatically causes a “broken libido,” nor does it mean one pink pill turns every Tuesday night into a romance novel. Sexual desire is influenced by hormones, sleep, stress, physical comfort, medications, relationships, mood, self-image, and whether anyone remembered to unload the dishwasher. Still, the approval matters because it recognizes that sexual well-being does not expire when menstrual periods do.
This guide explains what the new FDA approval means, who may benefit, how Addyi works, what the research showed, and why treating low desire after menopause often requires more than one solution.
What Did the FDA Actually Approve?
The medication making headlines is Addyi, the brand name for flibanserin. It is a prescription tablet taken once daily at bedtime. Addyi was originally approved in 2015 for certain premenopausal women with acquired, generalized hypoactive sexual desire disorder, commonly called HSDD.
In December 2025, the FDA approved an expanded indication allowing Addyi to be used in women under age 65 regardless of whether they are premenopausal or postmenopausal. The updated label specifically includes women with acquired, generalized HSDD whose low sexual desire causes significant distress or interpersonal difficulty.
That wording matters. The approval is not for every woman who occasionally feels “not in the mood.” Desire naturally rises and falls across life, relationships, seasons, stress levels, and even laundry cycles. HSDD is more specific: it involves ongoing low desire that is distressing to the person and is not better explained by another medical condition, psychiatric condition, relationship issue, or medication effect.
Who Is Eligible for Addyi?
Under the current FDA-approved labeling, Addyi may be considered for women who:
- Are younger than 65 years old.
- Have acquired HSDD, meaning they previously did not have persistent low sexual desire.
- Have generalized HSDD, meaning low desire occurs across situations, partners, or types of sexual activity.
- Feel significant personal distress or relationship difficulty because of their low desire.
- Do not have another clear cause, such as a medication side effect, untreated depression, major relationship conflict, or another medical condition.
The medication is not approved as a general sexual-performance enhancer. It is also not a quick-fix “date night pill” and should not be confused with medications used for erectile dysfunction. Addyi is taken daily and works gradually over time.
Why Sex Drive Can Change After Menopause
Postmenopause begins after a person has gone 12 consecutive months without a menstrual period. It lasts for the rest of life. Hormone levels change during and after menopause, but every woman’s experience is different. Some women report little change in sexual desire, while others notice a sharp decline in interest, arousal, comfort, or satisfaction.
Declining estrogen can contribute to vaginal dryness, thinner vaginal tissues, reduced elasticity, and discomfort during sex. If intercourse hurts, the brain may reasonably decide that sex is not exactly a top-priority recreational activity. This is not a failure of desire; it is often a protective response to discomfort.
Other common contributors to lower libido after menopause include:
- Sleep disruption from hot flashes or night sweats.
- Stress related to work, caregiving, finances, or family responsibilities.
- Anxiety, depression, or body-image changes.
- Medications, including some antidepressants and blood pressure drugs.
- Chronic pain, diabetes, thyroid disorders, cardiovascular disease, and other health conditions.
- Relationship tension, poor communication, or mismatched expectations around intimacy.
That is why a good evaluation should look beyond hormones alone. Low libido is often not one problem with one cause. It is more like a group project where everyone forgot to check the shared document.
How Addyi Works for Low Sexual Desire
Addyi is a nonhormonal medication. It affects certain brain chemicals involved in sexual desire, including serotonin and dopamine pathways. Unlike erectile dysfunction medications, which may affect blood flow and are typically taken around sexual activity, Addyi is designed to be taken every night at bedtime.
The goal is not to create a sudden, dramatic urge on command. Instead, the medication may help some women experience more sexual desire, less distress about low desire, and a modest increase in satisfying sexual experiences over time.
That distinction is important because sexual desire is not a light switch. It is usually a combination of physical comfort, emotional safety, mental energy, relationship connection, and biology. A medication can potentially support one part of that picture, but it cannot fix untreated pain, resentment, exhaustion, poor sleep, or a partner who believes “foreplay” is asking, “You awake?”
What the Clinical Research Found
The FDA’s updated labeling includes research in naturally postmenopausal women younger than 65 with acquired, generalized HSDD. In the key 24-week clinical trial, women taking Addyi had statistically significant improvements in sexual desire, distress related to low desire, and satisfying sexual events compared with women taking placebo.
However, the benefit was modest, not magical. In the study, women taking Addyi had an average increase of about 0.9 satisfying sexual events per 28 days, compared with about 0.6 for placebo. That difference may be meaningful for some women, especially when low desire has become a source of distress. For others, it may not feel substantial enough to justify the medication’s risks or daily routine.
The study also showed improvement in sexual desire scores and a reduction in distress related to low desire. Still, clinical trial participants were relatively healthy and did not have major uncontrolled medical conditions or complicated medication regimens. Real-life patients often have more variables, which is one reason individualized medical guidance matters.
How Long Does It Take to Work?
Addyi is not intended to be judged after one or two doses. The FDA label recommends discontinuing treatment after eight weeks if there is no improvement. That gives patients and clinicians a reasonable checkpoint: if nothing meaningful has changed after about two months, the medication may not be the right fit.
Important Side Effects and Safety Warnings
Addyi has important safety warnings. It can cause low blood pressure, fainting, dizziness, sleepiness, fatigue, nausea, insomnia, dry mouth, and anxiety. Because it may cause drowsiness and affect alertness, it should be taken only at bedtime.
Alcohol is a major concern. The updated prescribing information warns that combining Addyi with alcohol too close to the dose can raise the risk of severe low blood pressure and fainting. Patients are advised to wait at least two hours after one or two standard alcoholic drinks before taking the bedtime dose. If they have consumed three or more standard drinks that evening, they should skip the dose.
Addyi is also contraindicated in people with liver impairment and in those taking moderate or strong CYP3A4 inhibitors, a group that includes certain medications used for infections, heart conditions, and other health issues. That is why a full medication review is essential before starting treatment.
In postmenopausal clinical trials, dizziness occurred in 7.9% of women taking Addyi versus 3.3% taking placebo. Somnolence occurred in 7.7% versus 1.8%, and nausea occurred in 6.6% versus 3.9%. About 9% of postmenopausal participants taking Addyi discontinued treatment because of side effects, compared with 5% receiving placebo.
None of this means the medication is automatically unsafe. It means it requires thoughtful prescribing, honest conversations about alcohol use and medications, and a willingness to stop if the downsides outweigh the benefits.
Low Desire Is Not Always the Main Problem
Sometimes what feels like low libido is actually low comfort. Vaginal dryness, burning, irritation, or pain during intercourse can quietly sabotage desire. Genitourinary syndrome of menopause, often called GSM, describes a group of menopause-related symptoms involving the vagina, vulva, bladder, and urinary system.
For women with dryness or painful sex, treatment may include vaginal moisturizers, water-based lubricants, low-dose vaginal estrogen, vaginal DHEA products, or other prescription options depending on the person’s medical history. Addressing pain first can sometimes improve desire without needing a libido medication at all.
In other cases, sleep problems, hot flashes, depression, anxiety, medication side effects, or relationship strain may be the larger issue. A woman who is exhausted, uncomfortable, worried, and carrying the mental load of an entire household does not necessarily need a stronger libido. She may need rest, support, relief from pain, and one uninterrupted hour where nobody asks where the good scissors are.
Other Treatment Options for Postmenopausal Low Libido
Addyi is an important new FDA-approved option, but it is not the only approach. Sexual health specialists often use a combination of treatments based on the cause of symptoms.
Address Vaginal Dryness and Pain
Lubricants can reduce friction during sex, while vaginal moisturizers may support tissue comfort between sexual activity. For persistent menopause-related dryness and painful intercourse, clinicians may recommend local vaginal estrogen or other prescription therapies.
Review Medications and Health Conditions
Some medications can lower sexual desire or make arousal more difficult. A clinician may review antidepressants, blood pressure medication, sleep medicines, pain medications, and other prescriptions. Never stop a medication suddenly on your own, but do bring up changes in desire if they began after starting a new treatment.
Consider Counseling or Sex Therapy
Sex therapy, individual counseling, couples counseling, and cognitive behavioral therapy can be helpful when emotional stress, body image, communication problems, anxiety, or relationship patterns are affecting intimacy. Research and expert guidance consistently emphasize that sexual concerns often respond best to a combination of medical, emotional, and relationship-focused care.
Discuss Testosterone Carefully
Testosterone is sometimes prescribed off-label for postmenopausal women with low sexual desire, especially when no other clear cause is found. Evidence suggests it may help some women, but no testosterone product is FDA-approved specifically for sexual dysfunction in women in the United States. Potential side effects include acne, increased facial hair, scalp hair changes, and other concerns. Long-term safety data remain limited.
How to Talk to Your Doctor About Low Sex Drive
Many women hesitate to bring up sexual concerns because they worry they will be dismissed, embarrassed, or told that low desire is simply part of getting older. It may be common, but common does not mean untreatable or unimportant.
A useful starting sentence can be simple: “My desire has changed, and it is bothering me.” You can also mention whether you have pain, dryness, sleep problems, hot flashes, mood changes, new medications, or relationship concerns.
Consider asking these questions:
- Could vaginal dryness or pain be affecting my desire?
- Could any of my medications be contributing?
- Do I meet the criteria for HSDD?
- Would Addyi be safe with my health history and current medications?
- Should I consider vaginal estrogen, counseling, pelvic floor therapy, or another treatment?
- What improvements should I realistically expect?
The best answer may involve medication, counseling, vaginal treatment, lifestyle changes, or several approaches at once. Sexual health is not frivolous. It is part of overall quality of life, connection, comfort, and confidence.
Experiences After Menopause: What Real Life Can Look Like
The following examples are fictional composite experiences based on common issues discussed in menopause and sexual-health care. They are included to illustrate how different the causes and solutions can be.
“I Thought I Was Just Tired Forever”
Maria, 58, had always considered herself affectionate and interested in sex. After menopause, though, she began avoiding intimacy. At first, she assumed her sex drive had disappeared. She felt guilty because her partner noticed the distance, and she worried that something was “wrong” with her.
During a medical appointment, Maria mentioned that sex had become uncomfortable and that she was waking up several times every night because of hot flashes. Her clinician explained that vaginal dryness, disrupted sleep, and stress can all affect desire. Maria began using a vaginal moisturizer, switched to a lubricant she actually liked, and started treatment for her severe hot flashes.
Within a few months, she did not suddenly become a person who wanted sex every day. But she felt more comfortable, less exhausted, and less anxious about intimacy. Her biggest surprise was realizing that low desire had not been the entire story. Pain and sleep deprivation had been doing most of the damage behind the scenes.
“The Problem Was Bigger Than Hormones”
Danielle, 61, felt frustrated because she still loved her partner but rarely wanted sex. She had assumed menopause was the only explanation. A more detailed conversation revealed that she had started an antidepressant about a year earlier, around the same time her libido changed.
Her prescribing clinician reviewed the medication plan and discussed options. Danielle also began counseling because depression and work stress had been draining her energy and affecting her body image. Her treatment did not involve a dramatic movie montage, a beach sunset, or a suspiciously expensive scented candle. It involved slow, practical changes: medication review, therapy, more sleep, and more open conversations with her partner.
Over time, Danielle reported feeling more connected to herself and less pressured to “perform.” Her experience was a reminder that sexual desire is closely connected to mental health, emotional safety, and physical well-being.
“A Medication Helped, But It Was Not the Whole Plan”
Angela, 55, had persistent low desire that caused significant personal distress. She had no major relationship problems, no painful intercourse, and no recent medication changes. After a thorough evaluation, her clinician diagnosed acquired, generalized HSDD and discussed Addyi as one possible treatment.
Angela decided to try the medication after reviewing the alcohol restrictions, possible dizziness, sleepiness, and drug-interaction risks. She took it at bedtime and paid attention to how she felt during the first few weeks. She noticed some mild morning fatigue at first, but it improved. After several weeks, she felt more spontaneous interest in intimacy and less upset about her desire level.
The medication did not transform her into a different person. Instead, she described it as “taking the brakes off a little.” She still benefited from regular exercise, time with her partner, and reducing late-night work. But for her, Addyi became one useful tool in a larger plan.
“We Had to Learn a New Version of Intimacy”
Linda, 63, and her spouse had been together for more than three decades. They had assumed that intimacy after menopause should look exactly like it did in their 30s. When it did not, both felt discouraged.
Couples counseling helped them talk about changing needs without blame. They learned to slow down, use more lubrication, communicate more directly, and stop treating sex like a test with a pass-or-fail score. They also expanded their definition of intimacy to include touch, affection, humor, and closeness without pressure.
Linda later said the biggest improvement was not a medication or a product. It was realizing that menopause did not end her sexual life; it simply required a different map.
Conclusion: A New Option, Not a One-Size-Fits-All Solution
The FDA’s expanded approval of Addyi for women under 65 regardless of reproductive status is a meaningful development in postmenopausal sexual health. It gives some women with acquired, generalized HSDD an FDA-approved, nonhormonal treatment option that was not previously available to them.
Still, low sexual desire after menopause is rarely caused by one factor. Hormonal changes, vaginal dryness, pain, sleep loss, mood, medications, health conditions, relationship dynamics, and stress can all play a role. The most effective approach often begins with an honest conversation and a full evaluation rather than a rush toward any single prescription.
For women whose low desire causes distress, the message is simple: you are not alone, you are not “too old” to care about intimacy, and you do not have to accept discomfort or disconnection as inevitable. Modern menopause care has more options than ever, and your sexual well-being deserves a seat at the table.
